Trials / Recruiting
RecruitingNCT06681051
Effectiveness and Safety of OSTENIL® TENDON in the Treatment of Pain and Restricted Mobility in Tendon Disorders
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 84 (estimated)
- Sponsor
- TRB Chemedica AG · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
PMCF study to further substantiate the effectiveness and safety of OSTENIL® TENDON in the overall as well as indication-specific treatment of pain and restricted mobility in four different tendon disorders (patella tendon, peroneal tendon, medial epicondylus humeri and iliotibial band) in a real-life clinical setting when used according to the instructions for use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | OSTENIL® TENDON | OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation. |
Timeline
- Start date
- 2024-11-25
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2024-11-08
- Last updated
- 2025-09-22
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT06681051. Inclusion in this directory is not an endorsement.